The difference in clinical responses between patients with SS and MF may partly be due to the intravenous administration of mogamulizumab, which exposes Sézary cells in the blood to high concentrations of anti-CCR4 antibodies. The gene discussed is CCR4; the disease is mycosis fungoides.